Pelage Pharmaceuticals

Funding and NIH signals

• SEC Form D raise Raised $120M (Form D filed Nov 24, 2025). SEC Form D 0001982875-25-000002 (Nov 24, 2025)
  Evidence (1 event)

  • Nov 24, 2025 · SEC Form D 0001982875-25-000002
    Name of Issuer: Pelage Pharmaceuticals, Inc.; CIK: 1982875; Address: Los Angeles, CA; Submission type: D; Filing date: 2025-11-24; Industry Group: Pharmaceuticals; Date of First Sale: 2025-09-18; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 119999987; Total Amount Sold: 119999987; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Raises and deals from press releases

• Raise Series B · $120M · announced Oct 15, 2025 Company release ↗
  Source quote

  • Oct 15, 2025 · Company release ↗
    “— Pelage Pharmaceuticals , a clinical-stage regenerative medicine biotechnology company, today announced the close of a $120 million Series B financing co-led by ARCH Venture Partners and GV (Google Ventures)”
• Raise Series A · $16.75M · announced Feb 27, 2024 Company release ↗
  Source quote

  • Feb 27, 2024 · Company release ↗
    “Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine for Hair Loss”

Raises announced in these releases: $136.75M disclosed.

From the company’s own releases; this list is partial. All raises and deals